BMHL vs UBCP

BMHL's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial health, but the absence of an Altman Z-Score limits bankruptcy risk assessment. Despite strong profitability metrics like a 30.26% ROE and low debt/equity of 0.09, the stock appears severely overvalued with a P/E of 73.90 versus a sector average of 20.86 and a Graham Number of just $0.48. Revenue growth is exceptional at 199.3% YoY, but earnings have declined by 43.4%, creating a fundamental disconnect. The technical trend is bearish, price performance over 1Y/3Y/5Y is negative, and insider sentiment is weak at 40/100, collectively signaling caution.

UBCP presents a compelling value opportunity, anchored by a Piotroski F-Score of 4/9 (Stable) and a current price of $15.90 that sits significantly below both its Graham Number ($19.22) and Intrinsic Value ($37.32). The company demonstrates robust top-line growth (17.4% YoY) and a sustainable dividend yield of 4.88%. While technical trends and insider sentiment are currently bearish, the fundamental valuation and earnings growth trajectory suggest a strong margin of safety.